Mid-Point Analysis of Pivotal Phase 3 SIERRA Trial Including Material Presented at 2020 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR (TCT)
225Ac-CD38 Antibody Targeting is Effective and Well Tolerated in Experimental Models of Lymphoma and Multiple Myeloma
Targeted Lymphodepletion with Radiolabeled CD45 antibody as a Preparative Regimen Prior to Adoptive Cell Therapy